Evox Therapeutics Ltd, a leading exosome therapeutics company, announced that the company has been granted another key patent by the European Patent Office (EPO). This new grant reinforces the company's leading position within field of exosome therapeutics and adds to the growing number of foundational patent families within the Evox IP portfolio.The recently granted European patent (EP3463465) provides coverage for exosomes and methods of producing exosomes comprising an endogenous polypeptide-based release system for enabling luminal loading of soluble proteins inside an exosome. Such a release mechanism is important for optimal functional exosome-mediated delivery of soluble therapeutic proteins and enzymes into recipient cells.Dr Antonin de Fougerolles, chief executive officer of Evox, commented, "We are pleased to have been granted another important patent within our rapidly growing therapeutic exosome patent estate. This patent provides broad protection for our internal pipeline programs, where we are using this approach to functionally deliver soluble enzymes into cells in order to correct rare metabolic diseases. It is also broadly applicable to delivery of other types of drug payloads where luminal loading inside an exosome is important
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!